Literature DB >> 19889884

If the KI is defined by the free energy of binding to P-glycoprotein, which kinetic parameters define the IC50 for the Madin-Darby canine kidney II cell line overexpressing human multidrug resistance 1 confluent cell monolayer?

Annie Albin Lumen1, Poulomi Acharya, Joseph W Polli, Andrew Ayrton, Harma Ellens, Joe Bentz.   

Abstract

From previous fits of drug transport kinetics across confluent Madin-Darby canine kidney II cell line overexpressing human multidrug resistance 1 cell monolayers, we found that a drug's binding constant to P-glycoprotein (P-gp) was significantly smaller than its IC(50) when that drug was used as an inhibitor against another P-gp substrate. We tested several IC(50) candidate functions, including the standard function, the Kalvass-Pollack function, and the efflux ratio, to determine whether any of them yielded an IC(50) = K(I), as would be expected for water-soluble enzymes. For the confluent cell monolayer, the IC(50)/K(I) ratio is greater than 1 for all candidate functions tested. From the mass action kinetic model, we have derived a simple approximate equation that shows how the IC(50)/K(I) ratio depends on the elementary rate constants from our mass action model. Thus, the IC(50) will differ between cell lines and tissues, for the same probe substrate and inhibitor, if there are different membrane concentrations of P-gp, or the probe substrate's elementary rate constants, partition coefficient, binding constant to P-gp, passive permeability, and ability to access the other transporters (if any) in the two cell lines. The mass action model and the approximate equation for the IC(50)/K(I) ratio derived here can be used to estimate the elementary rate constants needed to extrapolate in vitro drug-drug interactions for compounds to the in vivo environment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889884     DOI: 10.1124/dmd.109.029843

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

1.  Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data.

Authors:  M Bauer; M Zeitlinger; R Karch; P Matzneller; J Stanek; W Jäger; M Böhmdorfer; W Wadsak; M Mitterhauser; J P Bankstahl; W Löscher; M Koepp; C Kuntner; M Müller; Oliver Langer
Journal:  Clin Pharmacol Ther       Date:  2011-12-14       Impact factor: 6.875

2.  The importance of villous physiology and morphology in mechanistic physiologically-based pharmacokinetic models.

Authors:  Emile P Chen; Guoying Tai; Harma Ellens
Journal:  Pharm Res       Date:  2013-08-30       Impact factor: 4.200

3.  Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.

Authors:  Joe Bentz; Michael P O'Connor; Dallas Bednarczyk; Joann Coleman; Caroline Lee; Johan Palm; Y Anne Pak; Elke S Perloff; Eric Reyner; Praveen Balimane; Marie Brännström; Xiaoyan Chu; Christoph Funk; Ailan Guo; Imad Hanna; Krisztina Herédi-Szabó; Kate Hillgren; Libin Li; Evelyn Hollnack-Pusch; Masoud Jamei; Xuena Lin; Andrew K Mason; Sibylle Neuhoff; Aarti Patel; Lalitha Podila; Emile Plise; Ganesh Rajaraman; Laurent Salphati; Eric Sands; Mitchell E Taub; Jan-Shiang Taur; Dietmar Weitz; Heleen M Wortelboer; Cindy Q Xia; Guangqing Xiao; Jocelyn Yabut; Tetsuo Yamagata; Lei Zhang; Harma Ellens
Journal:  Drug Metab Dispos       Date:  2013-04-25       Impact factor: 3.922

Review 4.  Computational approaches to analyse and predict small molecule transport and distribution at cellular and subcellular levels.

Authors:  Kyoung Ah Min; Xinyuan Zhang; Jing-yu Yu; Gus R Rosania
Journal:  Biopharm Drug Dispos       Date:  2013-12-10       Impact factor: 1.627

Review 5.  ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.

Authors:  M J Zamek-Gliszczynski; C A Lee; A Poirier; J Bentz; X Chu; H Ellens; T Ishikawa; M Jamei; J C Kalvass; S Nagar; K S Pang; K Korzekwa; P W Swaan; M E Taub; P Zhao; A Galetin
Journal:  Clin Pharmacol Ther       Date:  2013-02-25       Impact factor: 6.875

6.  Cationic uremic toxins affect human renal proximal tubule cell functioning through interaction with the organic cation transporter.

Authors:  Carolien M S Schophuizen; Martijn J Wilmer; Jitske Jansen; Lena Gustavsson; Constanze Hilgendorf; Joost G J Hoenderop; Lambert P van den Heuvel; Rosalinde Masereeuw
Journal:  Pflugers Arch       Date:  2013-06-29       Impact factor: 3.657

7.  Case Study 8: Status of the Structural Mass Action Kinetic Model of P-gp-Mediated Transport Through Confluent Cell Monolayers.

Authors:  Joe Bentz; Harma Ellens
Journal:  Methods Mol Biol       Date:  2021

8.  Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography.

Authors:  Florian Bauer; Thomas Wanek; Severin Mairinger; Johann Stanek; Michael Sauberer; Claudia Kuntner; Zahida Parveen; Peter Chiba; Markus Müller; Oliver Langer; Thomas Erker
Journal:  Eur J Pharmacol       Date:  2012-09-26       Impact factor: 4.432

9.  Fitting the elementary rate constants of the P-gp transporter network in the hMDR1-MDCK confluent cell monolayer using a particle swarm algorithm.

Authors:  Deep Agnani; Poulomi Acharya; Esteban Martinez; Thuy Thanh Tran; Feby Abraham; Frank Tobin; Harma Ellens; Joe Bentz
Journal:  PLoS One       Date:  2011-10-18       Impact factor: 3.240

10.  Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.

Authors:  Annie Albin Lumen; Libin Li; Jiben Li; Zeba Ahmed; Zhou Meng; Albert Owen; Harma Ellens; Ismael J Hidalgo; Joe Bentz
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.